HIPEC Surgery

HIPEC stands for hyperthermic intraperitoneal chemotherapy. It is performed during surgery after the surgeon has removed as much visible disease as safely possible. A heated chemotherapy solution is then circulated directly within the abdominal cavity for a limited period to treat remaining microscopic disease on peritoneal surfaces.

Because HIPEC is part of an operation, it should be thought of as a treatment plan that combines surgery and chemotherapy rather than as a separate infusion alone.

HIPEC delivers chemotherapy directly into the abdomen while the solution is warmed. This approach is designed to expose peritoneal surfaces to chemotherapy at the time of surgery, after visible tumor has been reduced as much as possible.

The exact drugs, timing, and technique depend on the protocol and the clinical situation. HIPEC is not suitable for every patient with abdominal cancer spread, and the appropriateness of the approach must be assessed carefully.

HIPEC may be considered in selected cancers that involve the peritoneum, especially when a cytoreductive operation is already being planned. The decision depends on whether the disease pattern, surgical findings, and overall condition make the combined approach reasonable.

Not every patient with advanced disease is a candidate. Some patients benefit more from standard surgery, systemic treatment, or another pathway based on the full clinical picture.

HIPEC is most often discussed in gynecologic oncology in relation to selected ovarian, fallopian tube, or primary peritoneal cancers where peritoneal spread is part of the disease pattern. It may be considered in carefully selected cases, often alongside cytoreductive surgery and broader treatment planning.

The role of HIPEC is not identical for every ovarian cancer scenario. Timing, prior chemotherapy, disease distribution, and the ability to achieve safe tumor reduction all matter.

HIPEC is not a routine treatment for uterine cancer, but it may enter discussion in selected complex situations involving peritoneal disease or unusual patterns of spread. Whether it is relevant depends on pathology, disease extent, prior treatment, and the judgment of the treating team.

Because these situations are uncommon and highly individualized, specialist review is essential before considering HIPEC in uterine cancer care.

At a high level, the operation begins with cytoreductive surgery to remove as much visible tumor as safely possible. After that, the heated chemotherapy solution is circulated within the abdominal cavity for a defined period before the operation is completed.

The exact surgical steps vary, and detailed planning depends on the disease pattern, the organs involved, and the patient?s condition. The goal is safe treatment planning, not a fixed technical recipe for every case.

Because HIPEC is combined with major abdominal surgery, recovery is usually longer than recovery after a simple outpatient treatment. Patients may need close monitoring in the hospital, pain control, support with nutrition and bowel recovery, and careful review for complications before discharge.

Recovery time varies with the extent of surgery, the patient?s overall health, and whether any complications arise. It is important for patients to ask what the realistic recovery path may look like in their specific situation.

Risks may include infection, bleeding, bowel-related complications, delayed recovery, kidney stress, fluid shifts, or complications related to major abdominal surgery. The balance between benefit and risk should be discussed carefully before treatment is chosen.

Follow-up after HIPEC may include wound review, blood tests, symptom monitoring, and planning for any further chemotherapy or surveillance. Patients should seek prompt guidance for fever, worsening abdominal pain, vomiting, dehydration, breathing trouble, or sudden deterioration after discharge.

HIPEC is a complex treatment strategy that requires careful case selection and coordinated planning. It is not defined by the procedure name alone; it depends on diagnosis, disease distribution, the feasibility of cytoreduction, general fitness for surgery, and the overall goals of treatment.

Specialist-led planning helps make sure the decision is based on the full clinical picture rather than on the appeal of an aggressive-sounding procedure.